Two pharma companies developing lipid-lowering drugs, MSD and Ionis, have reported positive phase 3 data that open the way for regulatory filings in the coming months. First up, MSD, which chalked up ...
Lauren (Hansen) Holznienkemper is a lead editor for the small business vertical at Forbes Advisor, specializing in HR, payroll and recruiting solutions for small businesses. Using research and writing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback